FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2793965220> ?p ?o ?g. }

• W2793965220 abstract "Background: Palbociclib (PAL) is an oral cyclin-dependent kinase (CDK) 4/6 inhibitor that is under investigation in multiple oncologic clinical trials and is currently approved for use in combination with aromatase inhibitors (AIs) or fulvestrant (FUL) in patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2–) advanced breast cancer (BC). The PEARL Study is an ongoing international, open label, controlled, randomized Phase 3 study comparing the efficacy and safety of PAL in combination with endocrine therapy (exemestane [EXE] or FUL) versus capecitabine in postmenopausal women with HR+/ HER2– metastatic BC whose disease progressed on AIs. A secondary objective of the study was to evaluate the pharmacokinetics (PK) of PAL (125mg QD, 3 weeks on/1 week off) and (25mg QD, continuously) when coadministered. This is the first study to investigate the drug-drug interaction (DDI) potential of the combination of PAL and the AI EXE. Methods: Patients (pts) randomized to the arm of the PEARL Study in seven selected sites had the option of participating in the PK sub-study. Those who enrolled in the PK sub-study received alone in a 7-day lead-in period immediately prior to Cycle 1 Day 1, when both drugs were coadministered on their standard dosing regimens. Sub-study pts were to have 2 pre-dose plasma PK samples drawn at steady-state (ss) during the lead-in period (EXE Alone) for determination, and 2 ss PK samples drawn for and PAL determination (2 per analyte) during coadministration (PAL+EXE). Plasma concentrations of PAL and were measured using validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods. The withinpatient mean concentration of the PK samples which met ss acceptance criteria (WPM-C trough ) for each analyte were generated for each treatment period as the input for DDI analyses. To assess the effect of coadministration of PAL on PK, the WPM-C trough of was compared within patients between the PAL+EXE (Test) and EXE Alone (Reference) treatment periods using a one-way analysis of variance (ANOVA) model with treatment as a fixed effect and patient as a random effect. To assess the effect of coadministration of on PAL PK, the WPM-C trough of PAL was compared between the PAL+EXE period (Test) and historical data (Reference) using an ANOVA model. Analysis of covariance (ANCOVA) models were used to assess the impact of demographic differences between analysis populations in covariates known to impact PAL PK on the ANOVA model conclusions. Results: A total of 26 pts randomized to the arm were enrolled in the PK sub-study and had PK samples analysed, of which 23 meet ss acceptance criteria. The ratio of the adjusted geometric means for WPM-C trough was 106.9% (90%CI: 82.4-138.8), when was administered with PAL, compared with its administration alone. Likewise, the models to assess potential for to perpetrate DDI on PAL PK showed ratios of adjusted geometric means of 102.4% (90%CI: 82.0-127.9) and 111.6% (90%CI: 90.3137.8), when adjusted for covariates. Conclusion: The PK data indicate a lack of a clinically meaningful DDI between PAL and when the 2 drugs are coadministered. Sponsor: GEICAM Citation Format: Martin M, Hoffman J, Ruiz-Borrego M, Munoz M, Calvo L, Crownover P, Garcia-Saenz JA, Alba E, Wang D, Thallinger C, Stradella A, Montano A, Adamo B, Antolin S, Moreno-Anton F, Falo C, Ruiz V, Martin N, Caballero R, Carrasco E, Gil-Gil M. Evaluation of the drug interaction potential of palbociclib and exemestane – Results from the PEARL pharmacokinetic sub-Study [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-21-23." @default.
• W2793965220 created "2018-03-29" @default.
• W2793965220 creator A5006511628 @default.
• W2793965220 creator A5006553047 @default.
• W2793965220 creator A5007561793 @default.
• W2793965220 creator A5029121049 @default.
• W2793965220 creator A5032379353 @default.
• W2793965220 creator A5033968813 @default.
• W2793965220 creator A5035176889 @default.
• W2793965220 creator A5035270880 @default.
• W2793965220 creator A5036532311 @default.
• W2793965220 creator A5039927103 @default.
• W2793965220 creator A5040451692 @default.
• W2793965220 creator A5045301167 @default.
• W2793965220 creator A5062510457 @default.
• W2793965220 creator A5065072315 @default.
• W2793965220 creator A5069553021 @default.
• W2793965220 creator A5075937719 @default.
• W2793965220 creator A5077375027 @default.
• W2793965220 creator A5081625911 @default.
• W2793965220 creator A5081743243 @default.
• W2793965220 creator A5084517455 @default.
• W2793965220 creator A5089703479 @default.
• W2793965220 date "2018-02-14" @default.
• W2793965220 modified "2023-09-26" @default.
• W2793965220 title "Abstract P5-21-23: Evaluation of the drug interaction potential of palbociclib and exemestane – Results from the PEARL pharmacokinetic sub-Study" @default.
• W2793965220 doi "https://doi.org/10.1158/1538-7445.sabcs17-p5-21-23" @default.
• W2793965220 hasPublicationYear "2018" @default.
• W2793965220 type Work @default.
• W2793965220 sameAs 2793965220 @default.
• W2793965220 citedByCount "1" @default.
• W2793965220 countsByYear W27939652202018 @default.
• W2793965220 crossrefType "proceedings-article" @default.
• W2793965220 hasAuthorship W2793965220A5006511628 @default.
• W2793965220 hasAuthorship W2793965220A5006553047 @default.
• W2793965220 hasAuthorship W2793965220A5007561793 @default.
• W2793965220 hasAuthorship W2793965220A5029121049 @default.
• W2793965220 hasAuthorship W2793965220A5032379353 @default.
• W2793965220 hasAuthorship W2793965220A5033968813 @default.
• W2793965220 hasAuthorship W2793965220A5035176889 @default.
• W2793965220 hasAuthorship W2793965220A5035270880 @default.
• W2793965220 hasAuthorship W2793965220A5036532311 @default.
• W2793965220 hasAuthorship W2793965220A5039927103 @default.
• W2793965220 hasAuthorship W2793965220A5040451692 @default.
• W2793965220 hasAuthorship W2793965220A5045301167 @default.
• W2793965220 hasAuthorship W2793965220A5062510457 @default.
• W2793965220 hasAuthorship W2793965220A5065072315 @default.
• W2793965220 hasAuthorship W2793965220A5069553021 @default.
• W2793965220 hasAuthorship W2793965220A5075937719 @default.
• W2793965220 hasAuthorship W2793965220A5077375027 @default.
• W2793965220 hasAuthorship W2793965220A5081625911 @default.
• W2793965220 hasAuthorship W2793965220A5081743243 @default.
• W2793965220 hasAuthorship W2793965220A5084517455 @default.
• W2793965220 hasAuthorship W2793965220A5089703479 @default.
• W2793965220 hasConcept C112705442 @default.
• W2793965220 hasConcept C121608353 @default.
• W2793965220 hasConcept C126322002 @default.
• W2793965220 hasConcept C143998085 @default.
• W2793965220 hasConcept C2775860665 @default.
• W2793965220 hasConcept C2775930923 @default.
• W2793965220 hasConcept C2777176818 @default.
• W2793965220 hasConcept C2777288759 @default.
• W2793965220 hasConcept C2777909004 @default.
• W2793965220 hasConcept C2779744173 @default.
• W2793965220 hasConcept C2780482068 @default.
• W2793965220 hasConcept C526805850 @default.
• W2793965220 hasConcept C530470458 @default.
• W2793965220 hasConcept C71924100 @default.
• W2793965220 hasConcept C84606932 @default.
• W2793965220 hasConcept C98274493 @default.
• W2793965220 hasConceptScore W2793965220C112705442 @default.
• W2793965220 hasConceptScore W2793965220C121608353 @default.
• W2793965220 hasConceptScore W2793965220C126322002 @default.
• W2793965220 hasConceptScore W2793965220C143998085 @default.
• W2793965220 hasConceptScore W2793965220C2775860665 @default.
• W2793965220 hasConceptScore W2793965220C2775930923 @default.
• W2793965220 hasConceptScore W2793965220C2777176818 @default.
• W2793965220 hasConceptScore W2793965220C2777288759 @default.
• W2793965220 hasConceptScore W2793965220C2777909004 @default.
• W2793965220 hasConceptScore W2793965220C2779744173 @default.
• W2793965220 hasConceptScore W2793965220C2780482068 @default.
• W2793965220 hasConceptScore W2793965220C526805850 @default.
• W2793965220 hasConceptScore W2793965220C530470458 @default.
• W2793965220 hasConceptScore W2793965220C71924100 @default.
• W2793965220 hasConceptScore W2793965220C84606932 @default.
• W2793965220 hasConceptScore W2793965220C98274493 @default.
• W2793965220 hasLocation W27939652201 @default.
• W2793965220 hasOpenAccess W2793965220 @default.
• W2793965220 hasPrimaryLocation W27939652201 @default.
• W2793965220 hasRelatedWork W1973342720 @default.
• W2793965220 hasRelatedWork W2080182535 @default.
• W2793965220 hasRelatedWork W2123709211 @default.
• W2793965220 hasRelatedWork W2278522493 @default.
• W2793965220 hasRelatedWork W2319584763 @default.
• W2793965220 hasRelatedWork W2319659376 @default.
• W2793965220 hasRelatedWork W2327145492 @default.
• W2793965220 hasRelatedWork W2341138420 @default.
• W2793965220 hasRelatedWork W2407589421 @default.
• W2793965220 hasRelatedWork W2560345223 @default.
• W2793965220 hasRelatedWork W2567716416 @default.

• next